These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 18424763)

  • 1. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
    Binyamin L; Alpaugh RK; Hughes TL; Lutz CT; Campbell KS; Weiner LM
    J Immunol; 2008 May; 180(9):6392-401. PubMed ID: 18424763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
    Terszowski G; Klein C; Stern M
    J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
    Du J; Lopez-Verges S; Pitcher BN; Johnson J; Jung SH; Zhou L; Hsu K; Czuczman MS; Cheson B; Kaplan L; Lanier LL; Venstrom JM
    Cancer Immunol Res; 2014 Sep; 2(9):878-89. PubMed ID: 24958280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
    Wang SY; Racila E; Taylor RP; Weiner GJ
    Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
    Kohrt HE; Thielens A; Marabelle A; Sagiv-Barfi I; Sola C; Chanuc F; Fuseri N; Bonnafous C; Czerwinski D; Rajapaksa A; Waller E; Ugolini S; Vivier E; Romagné F; Levy R; Bléry M; André P
    Blood; 2014 Jan; 123(5):678-86. PubMed ID: 24326534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
    Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
    Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
    Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
    Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
    Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
    Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.
    Wang SY; Veeramani S; Racila E; Cagley J; Fritzinger DC; Vogel CW; St John W; Weiner GJ
    Blood; 2009 Dec; 114(26):5322-30. PubMed ID: 19805620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present.
    Kern DJ; James BR; Blackwell S; Gassner C; Klein C; Weiner GJ
    Leuk Lymphoma; 2013 Nov; 54(11):2500-5. PubMed ID: 23452151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
    Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R
    Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
    Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
    J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma.
    Enqvist M; Jacobs B; Junlén HR; Schaffer M; Melén CM; Friberg D; Wahlin BE; Malmberg KJ
    Front Immunol; 2019; 10():2085. PubMed ID: 31572357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.